

Claims

What is claimed is:

1. A method of inhibiting the growth of a cancerous cell, comprising contacting the cell with an effective amount of RhoB protein, or a variant thereof, wherein the RhoB protein, or a variant thereof, inhibits at least one activity of the cell selected from the group consisting of migration, invasion, and metastasis.
2. The method of claim 1, wherein said method further comprises administering an additional anti-cancer agent to the cell.
3. The method of claim 2, wherein the additional anti-cancer agent comprises a cytotoxic agent or an anti-signaling agent.
4. The method of claim 2, wherein the RhoB protein, or a variant thereof, sensitizes the cell to the anti-cancer agent.
5. The method of claim 1, wherein said contacting comprises introducing a nucleic acid sequence encoding the RhoB protein, or a variant thereof, into the cell, whereby the nucleic acid sequence is expressed within the cell.
6. The method of claim 1, wherein said contacting comprises introducing the RhoB protein, or a variant thereof, into the cell.
7. The method of claim 1, wherein the RhoB protein, or a variant thereof, is associated with a pharmaceutically acceptable carrier.
8. The method of claim 1, wherein the RhoB protein, or a variant thereof, is associated with a pharmaceutically acceptable carrier comprising a targeting molecule.
9. The method of claim 1, wherein the cell is a solid tumor cell.

10. The method of claim 1, wherein said contacting comprises introducing a nucleic acid sequence encoding the RhoB protein, or a variant thereof, into the cell *in vivo* while the cell is present within a patient, and wherein the nucleic acid sequence is expressed within the cell, thereby producing the RhoB protein, or a variant thereof.

11. The method of claim 1, wherein said contacting comprises introducing the RhoB protein, or a variant thereof, into the cell *in vivo*, while the cell is present within a patient.

12. The method of claim 1, wherein said contacting is carried out *in vitro*.

13. The method of claim 1, wherein the cell has been transformed by at least one oncogene selected from the group consisting of H-Ras, N-Ras, K-Ras, EGFR, and ErbB2.

14. The method of claim 1, wherein the cell is not a v-src transformed cell.

15. A method of inhibiting malignant transformation of a cell, comprising administering to the cell an effective amount of RhoB protein, or a variant thereof, wherein the malignant transformation is not caused by the v-src oncogene.

16. The method of claim 15, wherein the malignant transformation is caused by at least one oncogene selected from the group consisting of H-Ras, N-Ras, K-Ras, EGFR, and ErbB2.